VANCOUVER, British Columbia–(BUSINESS WIRE)–ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced an extension to its option agreement to license the National Research Council of Canada’s (NRC) proprietary nanobody-based CD22 binder for use in Chimeric Antigen Receptor (CAR) therapy. ME Therapeutics will continue developing the CD